Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the UK, and Japan - is projected to experience significant growth ...

Its expansion is attributed to the treatment of ambulatory DMD patients. The Duchenne muscular dystrophy (DMD) market across ...

Oral Presentations: Abstract Title: Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping Date and Time: Wednesday ...

A substantial portion of this market growth is attributed to the treatment of ambulatory DMD patients. In 2023, exon-skipping therapies dominated the therapeutic landscape, generating approximately $1 ...

Adult men with DMD have over twice the fracture risk compared to non-DMD counterparts, with corticosteroids increasing this risk further. Bone health monitoring is inadequate, with less than half ...

The exon-skipping drug was approved by the FDA for DMD patients with mutations in the dystrophin gene amenable to exon 53 skipping, a group that accounts for around 8% of the total DMD population.

Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ...

Around 13% of DMD patients respond to exon 51 skipping, but PepGen reckons other drugs in its pipeline will address mutations that are central to around 35% of all cases of the disease.

Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping The FORCE™ Platform Achieves Robust and Durable DUX4 Suppression and ...

Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE ...